Advertisement

Covidien lands 510(k) clearance for its Nellcor bedside respiratory patient monitoring system, which aims to reduce costs and service disruptions.

Covidien logo

Medical device company Covidien (NYSE:COV) landed FDA 510(k) clearance and European CE Mark approval for the Nellcor bedside respiratory patient monitoring system, which will help clinicians detect and respond to dangerous respiratory events sooner, the company said.

The new Nellcor system can accommodate new parameters and features when monitoring blood oxygenation and pulse rate and it can reduce service disruptions and costs for hospitals, according to Covidien. 

Advertisement
Advertisement